Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Translational research: are we on the right track? 2008 American Society for Clinical Investigation Presidential Address.

Literature DB >> 18982165

Translational research: are we on the right track? 2008 American Society for Clinical Investigation Presidential Address.

Charles L Sawyers¹.

Abstract

Mesh：

Year: 2008 PMID： 18982165 PMCID： PMC2575723 DOI： 10.1172/JCI37557

Source DB: PubMed Journal: J Clin Invest ISSN： 0021-9738 Impact factor: 14.808

× No keyword cloud information.

17 in total

1. The history and evolution of the ASCI: déjà vu all over again. American Society for Clinical Investigation.

Authors: David Ginsburg
Journal: J Clin Invest Date: 2002-12 Impact factor: 14.808

2. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia.

Authors: E Shtivelman; B Lifshitz; R P Gale; E Canaani
Journal: Nature Date: 1985 Jun 13-19 Impact factor: 49.962

3. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining.

Authors: J D Rowley
Journal: Nature Date: 1973-06-01 Impact factor: 49.962

4. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase.

Authors: T Schindler; W Bornmann; P Pellicena; W T Miller; B Clarkson; J Kuriyan
Journal: Science Date: 2000-09-15 Impact factor: 47.728

5. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.

Authors: M E Gorre; M Mohammed; K Ellwood; N Hsu; R Paquette; P N Rao; C L Sawyers
Journal: Science Date: 2001-06-21 Impact factor: 47.728

6. Overriding imatinib resistance with a novel ABL kinase inhibitor.

Authors: Neil P Shah; Chris Tran; Francis Y Lee; Ping Chen; Derek Norris; Charles L Sawyers
Journal: Science Date: 2004-07-16 Impact factor: 47.728

7. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.

Authors: Neil P Shah; John M Nicoll; Bhushan Nagar; Mercedes E Gorre; Ronald L Paquette; John Kuriyan; Charles L Sawyers
Journal: Cancer Cell Date: 2002-08 Impact factor: 31.743

8. Cell lines and clinical isolates derived from Ph1-positive chronic myelogenous leukemia patients express c-abl proteins with a common structural alteration.

Authors: J B Konopka; S M Watanabe; J W Singer; S J Collins; O N Witte
Journal: Proc Natl Acad Sci U S A Date: 1985-03 Impact factor: 11.205

9. Localization of the c-ab1 oncogene adjacent to a translocation break point in chronic myelocytic leukaemia.

Authors: N Heisterkamp; J R Stephenson; J Groffen; P F Hansen; A de Klein; C R Bartram; G Grosveld
Journal: Nature Date: 1983 Nov 17-23 Impact factor: 49.962

10. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency.

Authors: Neil P Shah; Brian J Skaggs; Susan Branford; Timothy P Hughes; John M Nicoll; Ronald L Paquette; Charles L Sawyers
Journal: J Clin Invest Date: 2007-09 Impact factor: 14.808

5 in total

Review 1. Preclinical development of molecular-targeted agents for cancer.

Authors: Alberto Ocana; Atanasio Pandiella; Lillian L Siu; Ian F Tannock
Journal: Nat Rev Clin Oncol Date: 2010-12-07 Impact factor: 66.675

2. 2014 American Society for Clinical Investigation Presidential Address. Leading by example: pastors, mentors, physician-scientists, and the ASCI.

Authors: Peter Tontonoz
Journal: J Clin Invest Date: 2014-07-01 Impact factor: 14.808